Extract
With the advancement in diagnostics, therapeutics and dietary programmes, outcomes in cystic fibrosis (CF) have significantly improved for individuals fortunate enough to have access to care [1–4]. However, mortality in advanced CF remains high for those who do not receive lung transplant [5]. Efforts to increase access to lung transplant and/or reduce waitlist times are important.
Abstract
Prioritisation programmes for lung transplant like the high emergency lung transplantation programme in France have the potential to increase transplants in high-risk groups without worsening post-transplant outcomes https://bit.ly/3w1p8es
Footnotes
Author contributions: O.F. Bayomy, K.J. Ramos and C.H. Goss conceived and drafted the manuscript. All authors reviewed, revised and approved the final version submitted for publication and agree to be accountable for the work.
Conflict of interest: K.J. Ramos reports grants from National Institutes of Health, Cystic Fibrosis Foundation and CHEST Foundation in partnership with Vertex Pharmaceuticals, outside the submitted work.
Conflict of interest: C.H. Goss reports grants from Cystic Fibrosis Foundation, European Commission and NIH (NHLBI, NIDDK and NCRR), during the conduct of the study; personal fees for advisory board work from Gilead Sciences, personal fees for data monitoring committee work from Novartis, grants from NIH and FDA, other (lead in trial research) from Boehringer Ingelheim, other (honoraria for lectures) from Vertex Pharmaceuticals, outside the submitted work; none of the work presented in this opinion piece were influenced by the funding sources noted above; the funding sources that support other ongoing research played no role in writing this manuscript, or in the decision to submit for publication.
Conflict of interest: O.F. Bayomy has no conflicts to disclose.
Support statement: K.J. Ramos receives funding from the National Institutes of Health (NIH) K23HL138154, Cystic Fibrosis Foundation (CFF) RAMOS17A0, and a CHEST Foundation Cystic Fibrosis grant. C.H. Goss receives funding from the NIH (UM1 HL119073, P30 DK089507, U01 HL114589, UL1 TR000423), the Cystic Fibrosis Foundation and the FDA (R01 FD003704, R01 FD006848). Funding information for this article has been deposited with the Crossref Funder Registry.
- Received August 8, 2021.
- Accepted October 22, 2021.
- Copyright ©The authors 2022. For reproduction rights and permissions contact permissions{at}ersnet.org